Changchun High-tech's core subsidiary, Jinsai Pharmaceutical, strategically adjusts its organizational structure.

Jinsai Pharmaceutical, a leading company in the growth hormone industry, recently announced that they have proactively carried out a strategic organizational restructuring based on their assessment of the development trends and competitive landscape in the innovative pharmaceutical industry. Jinsai Pharmaceutical stated that this adjustment aims to optimize organizational efficiency and operational effectiveness, concentrating resources more on innovative research and development and core products to better meet future market demands. The company expressed their gratitude to all affected employees for their contributions and mentioned that they will provide appropriate support programs, including attention and necessary assistance to special employees. However, Jinsai Pharmaceutical did not provide detailed information on the specific departments and personnel involved in the restructuring. Additionally, they did not deny conducting a self-examination of reimbursement matters during the same period, stating that internal compliance checks are a routine practice for ensuring compliance within the company and are a necessary means to regulate employee financial management, unrelated to the current organizational restructuring strategy.